1.Photodynamic therapy guidelines for the management of oral leucoplakia.
Qianming CHEN ; Hongxia DAN ; Fan TANG ; Jiongke WANG ; Xiaoying LI ; Junxin CHENG ; Hang ZHAO ; Xin ZENG
International Journal of Oral Science 2019;11(2):14-14
With recent developments in photosensitizers and light delivery systems, topical 5-aminolevulinic acid-mediated photodynamic therapy (ALA-PDT) has become the fourth alternative therapeutic approach in the management of oral leucoplakia (OLK) due to its minimally invasive nature, efficacy, and low risk of systemic side effects and disfigurement. This report presents step-by-step guidelines for applying topical ALA-PDT in the management of OLK based on both the clinical experience of the authors and a systematic review of the current literature. Studies using protocols with standardized parameters and randomized clinical trials at multiple centres with adequate sample sizes and both interim and long-term follow-ups are needed before universally applicable guidelines can be produced in this field.
Aminolevulinic Acid
;
administration & dosage
;
therapeutic use
;
Humans
;
Leukoplakia, Oral
;
therapy
;
Photochemotherapy
;
methods
;
Photosensitizing Agents
;
administration & dosage
;
therapeutic use
;
Practice Guidelines as Topic
2.Structural and Functional Outcomes in Chronic Central Serous Chorioretinopathy Treated with Photodynamic Therapy.
Pino CIDAD ; Eugenia GONZALEZ ; Monica ASENCIO ; Jesus GARCIA
Korean Journal of Ophthalmology 2015;29(5):331-335
PURPOSE: To study the retinal pigment epithelium (RPE) and retinal alterations in chronic central serous chorioretinopathy treated with photodynamic therapy, and its correlation with functional parameters such as best-corrected visual acuity (BCVA) and contrast sensitivity (CS). METHODS: Retrospective, noncomparative, consecutive evaluation by optical coherence tomography and its correlation with BCVA and CS in 31 eyes of 26 patients. RESULTS: In all affected patients, 88.5% were male with a mean age of 42.9 years. The right eye was involved in 64.5% of cases, bilateral in 19% and 73.9% were hyperopic (spherical refraction between 0 and +5.0 diopters). Of these cases, 51.5% had peri-RPE abnormalities, 17.3% hyperreflective substances at RPE, 19.4% RPE atrophy, 55.3% foveolar atrophy, 3.1% pigment epithelial detachment, 5.2% subretinal fluid persistence, 8.3% fibrin deposits, 68.4% photoreceptor inner and outer segment line interruption and 31.1% external limiting membrane interruption. CONCLUSIONS: Time evolution and number of outbreaks were related to the decrease in foveal and chorodial thickness and in those with worse BCVA and CS. RPE abnormalities and atrophy were related to the age of onset of symptoms. Photoreceptor elongation has been correlated with poor BCVA and inner and outer segment line destructuring and interruption with poor CS.
Adult
;
Central Serous Chorioretinopathy/diagnosis/*drug therapy/physiopathology
;
Chronic Disease
;
Female
;
Fluorescein Angiography
;
Follow-Up Studies
;
Fundus Oculi
;
Humans
;
Male
;
Middle Aged
;
Photochemotherapy/*methods
;
Photosensitizing Agents/administration & dosage
;
Porphyrins/*administration & dosage
;
Retina/*diagnostic imaging/drug effects/physiopathology
;
Retrospective Studies
;
Tomography, Optical Coherence
;
Treatment Outcome
;
*Visual Acuity
3.Research progress of the anti-tumor effect of sonodynamic and photodynamic therapy.
Xiaomin SU ; Long LI ; Pan WANG
Journal of Biomedical Engineering 2012;29(3):583-587
Cancer, as a serious threat to human health, is one of the major killers. The treatment of cancer has attracted more and more attention. Currently, the means of treating cancer is also increasing, but there is no emergence of a fully satisfactory treatment. A combination of sonodynamic therapy (SDT) and photodynamic therapy (PDT), named sono-photodynamic therapy (S-PDT), is a new composite cancer therapy. Because the therapy can significantly improve the tumor curing effect, it has good application prospects in cancer prevention and treatment. The present article reviewed the progress of the anti-tumor mechanisms and influencing factors of S-PDT.
Animals
;
Antineoplastic Agents
;
administration & dosage
;
Combined Modality Therapy
;
Hematoporphyrin Derivative
;
administration & dosage
;
Hematoporphyrin Photoradiation
;
Humans
;
Neoplasms
;
drug therapy
;
therapy
;
Photochemotherapy
;
methods
;
Photosensitizing Agents
;
administration & dosage
;
Ultrasonic Therapy
;
methods
4.Combined Treatment of Photodynamic Therapy and Bevacizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration.
Hyun Woong KIM ; Jung Lim KIM ; Mi Hyun LEE ; Hyung Gon YOO ; In Young CHUNG ; Ji Eun LEE
Korean Journal of Ophthalmology 2011;25(4):231-237
PURPOSE: To evaluate the outcome of a combined photodynamic therapy and intravitreal injection of bevacizumab in choroidal neovascularization secondary to age-related macular degeneration. METHODS: Photodynamic therapy (PDT) was administered to 28 eyes followed by 3 consecutive bevacizumab injections. Patients were followed-up for more than 12 months. At baseline, 1, 3, 6, and 12 months post PDT, visual acuity (VA) and central macular thickness were measured using optical coherence tomography. RESULTS: The mean VA was significantly improved from logarithm of the minimal angle of resolution 0.86 at baseline to 0.69 at 1 month (p = 0.011), 0.63 at 3 months (p = 0.003), 0.64 at 6 months (p = 0.004) and 0.60 at 12 months (p < 0.001). Central macular thickness decreased significantly from 328.3 microm at baseline to 230.0 microm at 6 months and 229.9 microm at 1 year (p < 0.001). Reinjection mean number was 0.4 for 6 months and 0.8 for 12 months. By 1 year, retreatment was performed in 10 eyes (36%). CONCLUSIONS: PDT combined with three consecutive intraviteal bevacizumab injections was effective in improving VA and reducing central macular thickness.
Aged
;
Angiogenesis Inhibitors/*administration & dosage
;
Antibodies, Monoclonal, Humanized/*administration & dosage
;
Choroidal Neovascularization/diagnosis/*drug therapy/etiology
;
Dose-Response Relationship, Drug
;
Drug Therapy, Combination
;
Female
;
Fluorescein Angiography
;
Follow-Up Studies
;
Fundus Oculi
;
Humans
;
Intravitreal Injections
;
Macula Lutea/drug effects/*pathology
;
Macular Degeneration/*complications/diagnosis/drug therapy
;
Male
;
Photochemotherapy/*methods
;
Photosensitizing Agents/administration & dosage
;
Porphyrins/*administration & dosage
;
Retrospective Studies
;
Tomography, Optical Coherence
;
Treatment Outcome
;
Visual Acuity
5.Three stages of 5-aminolevulinic acid-photodynamic therapy for condyloma acuminatum of external urethral meatus.
Jie LI ; Yunlian YI ; Wu ZHU
Journal of Central South University(Medical Sciences) 2011;36(11):1115-1119
OBJECTIVE:
To observe the effect of the three stages of 5-aminolevulinic acid-photodynamic therapy (ALA-PDT) on condyloma acuminatum of external urethral meatus.
METHODS:
A total of 56 patients with condyloma acuminatum of external urethral meatus presenting at the Department of Dermatology of Xiangya Hospital from Janunary 2009 to September 2009 were randomly treated by the three stages of ALA-PDT. The topical ALA followed by PDT was carried out once a week for 3 weeks. Rates of cure, ineffectiveness, adverse effects and complications were observed. The follow-up time was 6 months and the recurrence rates were documented.
RESULTS:
After treatment of three stages of ALA-PDT, complete remission was achieved in 48 out of the 56 patients (85.7%). The recurrence rate was 14.3% (8 cases), and 2 patients had no responses (3.6%). Only 1 patient had serious pain during the treatment, and the rate of adverse effect was 1.8%. No complications were observed.
CONCLUSION
The three stages of ALA-PDT are safe, effective and tolerant treatment for condyloma acuminatum of external urethral meatus.
Adult
;
Aminolevulinic Acid
;
administration & dosage
;
Condylomata Acuminata
;
drug therapy
;
Humans
;
Male
;
Photochemotherapy
;
Photosensitizing Agents
;
administration & dosage
;
Urethral Diseases
;
drug therapy
6.Recent development of targeted drug delivery system.
Peng-ju ZHOU ; Sheng-qi DENG ; Qian-fei GONG
Acta Pharmaceutica Sinica 2010;45(3):300-306
Targeted drug delivery can significantly increase the concentration of the drug in treatment site, and decrease the dosage of drugs, cost of treatment and the drug's adverse effects on the body. So targeted drug delivery is the hotspot of recent studies. This paper reviews the development of targeted drug delivery research in recent years, including three areas: passive targeting, active targeting, and physical and chemical targeting.
Animals
;
Antibodies
;
metabolism
;
Drug Carriers
;
Drug Delivery Systems
;
methods
;
trends
;
Emulsions
;
Humans
;
Liposomes
;
Magnetics
;
Microspheres
;
Nanoparticles
;
Pharmaceutical Preparations
;
administration & dosage
;
Photosensitizing Agents
;
pharmacology
;
Prodrugs
;
Receptors, Cell Surface
;
metabolism
7.Effect of ultrasound activating hematoporphyrin on the activities of antioxidative enzymes in mouse hepatoma 22.
Xiaoying LI ; Li'na XIAO ; Pan WANG ; Wei TANG ; Longlong ZHANG ; Quanhong LIU
Journal of Biomedical Engineering 2009;26(4):825-841
This investigation was made with regard to the influences of ultrasound combined with hematoporphyrin on the activities of antioxidative enzyme in ascites hepatoma 22 (H-22) tumor cells, and to a better understanding of the potential biological mechanism of sonodynamic therapy which involved the damage to cells. Combined with 100 microg/ml hematoporphyrin, high intensity focused ultrasound sonication at a frequency of 1.43 MHz and an intensity level of 2.0 W/cm2 was delivered to H-22 tumor cells for 1 min. The viability of cells was evaluated by typan-blue blue exclusion test. The intracellular reactive oxygen species (ROS) levels were determined by 2',7'-dichlorofluorescein diacetata (DCFH-DA). Enzymatic chemical methods were used to measure the activities of key antioxidative enzymes. The results indicated that the cell damage rate of ultrasound combined with hematoporphyrin was significantly higher than that of the treatment with ultrasound alone, and hematoporphyrin alone had no killing effect on H-22 cells. The level of ROS in cell suspension was significantly increased, and the key antioxidative enzyme activities were obviously decreased after treatment with the combined use of ultrasound and hematoporphyrin. We speculated that the decreased activities of key antioxidative enzymes in cells might be involved in mediating the killing effect on H22 cells in sonodynamic therapy.
Animals
;
Female
;
Glutathione Peroxidase
;
metabolism
;
Hematoporphyrins
;
administration & dosage
;
radiation effects
;
Liver Neoplasms, Experimental
;
enzymology
;
therapy
;
Mice
;
Mice, Inbred ICR
;
Photochemotherapy
;
methods
;
Photosensitizing Agents
;
administration & dosage
;
radiation effects
;
Superoxide Dismutase
;
metabolism
;
Ultrasonics
8.A Case of Photodynamic Therapy for Early Esophageal Cancer Recurred after Esophagectomy.
Byeong Wha HA ; Jin Il KIM ; Eun Mi HWANG ; You Kyoung OH ; Dae Young CHEUNG ; Soo Heon PARK ; Jae Kwang KIM ; Kyu Yong CHOI
The Korean Journal of Gastroenterology 2007;49(5):331-335
Photodynamic therapy is a promising modality for the palliation of advanced upper gastrointestinal cancer and for the eradication of early neoplastic and pre-neoplastic lesions. It is based on the combination of a photosensitizer that is selectively localized in the target tissue and illumination of the lesion with visible light, resulting in photodamage and subsequent cell death. For early esophageal cancer, esophagectomy has been a standard modality of curative intent. However, accumulated data supports the possibility of PDT replacing surgery as a curative modality. We experienced a case of early esophageal cancer that recurred after esophagectomy. The patient was successfully treated with photodynamic therapy using porfimer sodium as a photosensitizer.
Endoscopy, Gastrointestinal
;
Esophageal Neoplasms/*drug therapy/pathology/surgery
;
*Esophagectomy
;
Humans
;
Male
;
Middle Aged
;
*Photochemotherapy
;
Photosensitizing Agents/administration & dosage/*therapeutic use
9.Delivery of Photosensitizers for Photodynamic Therapy.
The Korean Journal of Gastroenterology 2007;49(5):300-313
Photodynamic therapy (PDT) has been used to treat several types of cancer, and comprises intravascular administration of photosensitizer, uptake by cancer cells, and followed by irradiation of light of appropriate wavelength. Although PDT takes advantage of relative retention of photosensitizer by cancer cells, effective delivery of photosensitizing drugs is of great concern. Several delivery strategies have been employed in PDT. Photosensitizers can be delivered either by passive carriers such as liposomes, micelles, and polymeric particles, or by active targeting using cancer cell-directed ligands or antibodies. Although well-studied colloidal carriers effectively deliver photosensitizer to tumor cells, they are taken up by mononuclear phagocytic system. Delivery system using polymers is an attractive alternative to colloidal carriers, in which hydrophobic drugs are chemically or physically loaded to polymers. Though there are several steps to be solved, targeted delivery system utilizing receptors or antigens abundantly expressed on cancer cell theoretically provides a great deal of advantages over passive system. Selective uptake of photosensitizers by cancer cells may greatly enhance therapeutic efficacy as well as minimizing adverse effects resulting from accumulation in normal tissue. This review discusses various strategies for photosensitizer delivery that have been investigated to date.
Drug Delivery Systems
;
Humans
;
Liposomes/chemistry
;
Micelles
;
Neoplasms/*drug therapy
;
*Photochemotherapy
;
Photosensitizing Agents/*administration & dosage
;
Polymers/chemistry/therapeutic use
10.Retinal Capillary Hemangioma Treated with Verteporfin Photodynamic Therapy and Intravitreal Triamcinolone Acetonide.
Shin Cho SUH ; Sun Young JIN ; Seon Hee BAE ; Chul Gu KIM ; Jong Woo KIM
Korean Journal of Ophthalmology 2007;21(3):178-184
PURPOSE: To report a case of retinal capillary hemangioma treated with verteporfin photodynamic therapy combined with intravitreal triamcinolone acetonide. METHODS: A 15-year-old female presented with metamorphopsia in the left eye for 7 days. Examination showed peripheral endophytic retinal capillary hemangioma, macular edema, and a best-corrected visual acuity of 20/50. The hemangioma and macular edema were treated with verteporfin photodynamic therapy and intravitreal triamcinolone acetonide. RESULTS: After 5 months of follow-up, involution of the hemangioma, reduction of macular edema, decrease of the feeder and draining vessel diameter, and improvement of best-corrected visual acuity to 20/25 was seen. CONCLUSIONS: This verteporfin photodynamic therapy combined with intravitreal triamcinolone acetonide appeared to cause involution of the hemangioma with reduction in macular edema and improvement in visual acuity.
Adolescent
;
Female
;
Fundus Oculi
;
Glucocorticoids/*administration & dosage/therapeutic use
;
Hemangioma, Capillary/diagnosis/*drug therapy
;
Humans
;
Injections
;
*Photochemotherapy
;
Photosensitizing Agents/*therapeutic use
;
Porphyrins/*therapeutic use
;
Retinal Neoplasms/diagnosis/*drug therapy
;
Tomography, Optical Coherence
;
Triamcinolone Acetonide/*administration & dosage/therapeutic use
;
Ultrasonography
;
Vitreous Body

Result Analysis
Print
Save
E-mail